<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Basal insulin therapy is an integral part of the intensive management of type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> and it is also often used in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>An ideal insulin regimen in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> would mirror the 24-h insulin profile of a non-diabetic person, thereby preventing <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> without inducing <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Until recently, available insulins have pharmacokinetic disadvantages, compared to physiological insulin secretion </plain></SENT>
<SENT sid="3" pm="."><plain>Insulin detemir is a new basal insulin analogue recently available for commercial use in the UK </plain></SENT>
<SENT sid="4" pm="."><plain>Clinical trials have demonstrated lower fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> levels, lower variability in plasma <z:chebi fb="105" ids="17234">glucose</z:chebi>, predictable action profile and a reduced risk of nocturnal <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> and <z:mp ids='MP_0005456'>weight gain</z:mp>, compared to conventional basal insulins </plain></SENT>
<SENT sid="5" pm="."><plain>This study reviews the properties and potential use of insulin detemir </plain></SENT>
</text></document>